Drug Profile
Rusfertide - Protagonist Therapeutics
Alternative Names: PTG-300; Rusfertide acetate - Protagonist TherapeuticsLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Protagonist Therapeutics
- Class Antianaemics; Antineoplastics; Peptides
- Mechanism of Action Hepcidin replacements; Iron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Polycythaemia vera
- Phase II Haemochromatosis
- Discontinued Beta-thalassaemia; Myelodysplastic syndromes
Most Recent Events
- 31 Jan 2024 Protagonist Therapeutics and Takeda enters into a license and collaboration agreement for the development and commercialization of rusfertide
- 22 Jan 2024 Phase-III clinical trials in Polycythaemia vera (Treatment-experienced) in USA (SC) (NCT06033586)
- 09 Dec 2023 Pharmacodynamics and adverse events data from a phase II REVIVE open-label extension trial in Polycythaemia vera presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)